Nature Communications | EF1α Promoter-Driven GZMK+ Transcriptional Program Enhances CAR-T Cell Efficacy in Multiple Myeloma

This study reveals the decisive role of promoter selection in the in vivo expansion and persistence of CAR-T cells, providing critical experimental evidence for optimizing the molecular design of immunotherapeutic products for multiple myeloma.

 

Literature Overview

This article, titled 'The EF1α promoter of cilta-cel drives a highly effective GZMK+ transcriptional program,' published in Nature Communications, systematically investigates the molecular mechanisms underlying the clinical efficacy differences between two approved BCMA-targeted CAR-T therapies: cilta-cel and ide-cel. Through single-cell multi-omics analysis and a retrospective clinical cohort review, the study found that cilta-cel's superior efficacy does not stem from its unique nanobody binding domain, but rather from the EF1α promoter it employs, which drives a distinct GZMK+ transcriptional program. This program endows T cells with enhanced in vivo expansion capabilities and persistence.

Background Knowledge

Multiple myeloma is a hematologic malignancy. Although CAR-T therapy has made significant progress, the mechanisms behind efficacy differences among various products remain unclear. The primary bottleneck in current BCMA-targeted research lies in balancing T cell effector function with long-term persistence to avoid premature exhaustion. Previous perspectives have largely focused on differences in antigen-binding domains (such as scFvs versus nanobodies), overlooking the decisive impact of vector promoters on cell fate. This study focuses on a comparative analysis of the transcriptomic and epigenetic characteristics of cilta-cel and ide-cel in patients, aiming to elucidate how promoters (EF1α vs. MND) reshape T cell differentiation trajectories. Specifically, it investigates how they induce subpopulations with memory-like features that highly express GZMK and EOMES, thereby addressing the challenges of in vivo persistence and sustained cytotoxicity of CAR-T cells.

 

 

Research Methods and Experiments

The authors first constructed a real-world clinical cohort of 87 patients, utilizing flow cytometry to track CAR-T cell expansion kinetics and phenotypic characteristics at various time points. Subsequently, the research team performed DOGMA-seq single-cell multi-omics sequencing on 20,635 CAR+ cells from 13 patients, integrating transcriptomic and chromatin accessibility data to resolve cellular heterogeneity. To confirm the mechanism, researchers constructed lentiviral vectors with four different combinations (promoter × binding domain) and conducted in vivo efficacy and phenotypic validation in a multiple myeloma xenograft model (MM.1s cell line).

Key evidence showed that cilta-cel exhibited a peak expansion 10-fold higher than ide-cel in clinical samples, enriched with a CD27+CD28+ memory phenotype. Multi-omics analysis revealed that cilta-cel specifically enriched a GZMK+ transcriptional program, regulated by the EOMES transcription factor, without accompanying typical exhaustion markers. In preclinical models, simply replacing the MND promoter with the EF1α promoter was sufficient to recapitulate cilta-cel's expansion advantage, GZMK+ transcriptional signature, and tumor control capabilities under the same binding domain background, directly proving the core driving role of the promoter.

Key Conclusions and Perspectives

• cilta-cel demonstrates significantly higher peak expansion and persistence in patients, characterized by an enrichment of CD4+ and CD8+ T cell subpopulations expressing GZMK and EOMES, rather than the traditional exhausted phenotype.
• Promoter selection (EF1α vs. MND) is a critical determinant of CAR-T cell efficacy and transcriptional programs. The EF1α promoter can independently drive the GZMK+ transcriptional trajectory, an effect superior to differences in binding domains (VHH vs. scFv).
• GZMK+ cell subpopulations possess unique epigenetic features, including high accessibility of enhancer elements downstream of the GZMK locus and enrichment of EOMES binding sites, suggesting these subpopulations combine effector function with self-renewal capacity.
• In multiple myeloma xenograft models, altering only the promoter was sufficient to recapitulate the efficacy differences observed clinically, indicating that optimizing the promoter is an efficient strategy to enhance CAR-T product performance.

Research Significance and Prospects

This discovery has profound implications for drug development, suggesting that in the design of next-generation CAR-T cell therapies, priority should be given to screening promoter elements capable of driving memory-like differentiation and persistence, rather than focusing solely on binding domain optimization. For clinical monitoring, the expression levels of GZMK and EOMES can serve as novel biomarkers to predict CAR-T cell in vivo persistence and efficacy. Furthermore, this study offers a new perspective on disease modeling: when evaluating immunotherapeutic products, vector construction details (such as promoters) must be included in the consideration of Critical Quality Attributes (CQAs) to ensure that experimental models can accurately predict clinical translation outcomes.

 

 

Conclusion

Through rigorous clinical cohort analysis and mechanistic validation, this study overturns the traditional view that binding domain differences determine CAR-T cell efficacy, establishing the central role of promoter selection in shaping T cell fate. The EF1α promoter, by inducing a GZMK+ transcriptional program, endows T cells with the unique advantage of long-term survival and efficient cytotoxicity within the multiple myeloma microenvironment. This finding not only explains the efficacy differences between existing approved products but also provides clear molecular targets and optimization pathways for the rational design of future immunotherapeutic products. From the laboratory to the clinic, a deep understanding of how promoters regulate cellular transcriptional programs will be the cornerstone for improving cure rates in hematologic tumor immunotherapy and building a more robust care system.

 

Kevin Herrera, Sneha Mitra, Yuqing Sun, Christina S Leslie, and Karlo Perica. The EF1α promoter of cilta-cel drives a highly effective GZMK+ transcriptional program. Nature Communications.